The comorbidity and co-medication profile of patients with progressive supranuclear palsy
Creators: name: Greten, Stephan
name: Wegner, Florian
name: Jensen, Ida
name: Krey, Lea
name: Rogozinski, Sophia
name: Fehring, Meret
name: Heine, Johanne
name: Doll-Lee, Johanna
name: Pötter-Nerger, Monika
name: Zeitzschel, Molly
name: Hagena, Keno
name: Pedrosa, David J.
name: Eggers, Carsten
name: Bürk, Katrin
name: Trenkwalder, Claudia
name: Claus, Inga
name: Warnecke, Tobias
name: Süß, Patrick
name: Winkler, Jürgen
name: Gruber, Doreen
name: Gandor, Florin
name: Berg, Daniela
name: Paschen, Steffen
name: Classen, Joseph
name: Pinkhardt, Elmar H.
name: Kassubek, Jan
name: Jost, Wolfgang H.
name: Tönges, Lars
name: Kühn, Andrea A.
name: Schwarz, Johannes
name: Peters, Oliver
name: Dashti, Eman
name: Priller, Josef
name: Spruth, Eike J.
name: Krause, Patricia
name: Spottke, Annika
name: Schneider, Anja
name: Beyle, Aline
name: Kimmich, Okka
name: Donix, Markus
name: Haussmann, Robert
name: Brandt, Moritz
name: Dinter, Elisabeth
name: Wiltfang, Jens
name: Schott, Björn H.
name: Zerr, Inga
name: Bähr, Mathias
name: Buerger, Katharina
name: Janowitz, Daniel
name: Perneczky, Robert
name: Rauchmann, Boris-Stephan
name: Weidinger, Endy
name: Levin, Johannes
name: Katzdobler, Sabrina
name: Düzel, Emrah
name: Glanz, Wenzel
name: Teipel, Stefan
name: Kilimann, Ingo
name: Prudlo, Johannes
name: Gasser, Thomas
name: Brockmann, Kathrin
name: Hoffmann, Daniel C.
name: Klockgether, Thomas
name: Krause, Olaf
name: Heck, Johannes
name: Höglinger, Günter U.
name: Klietz, Martin
Publisher: name: Universität Ulm
Year: 2023
Subjects: subject: Progressive supranuclear palsy
subject: Comorbidities
subject: Polypharmacy
subject: Drug–drug interactions
subject: DDC 610 / Medicine &amp; health

description: Abstract Background Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients. Objectives To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease. Methods Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiD Klinik ®. Results In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions. Conclusions PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.